Borgström L, Asking L, Thorsson L
AstraZeneca R&D, Lund, Sweden.
Int J Clin Pract. 2005 Dec;59(12):1488-95. doi: 10.1111/j.1368-5031.2005.00747.x.
Medication for the treatment of asthma and chronic obstructive pulmonary disease should be given locally by inhalation. There is, however, no such thing as an ideal inhaler, or 'Idealhaler', which has all desired properties with no drawbacks. In this short review, we have compared the relative merits of the two most commonly used dry powder inhalers -- Turbuhaler and Diskus. Clinical effect is related to the amount of inhaled drug that reaches the lungs, and this in turn depends on the amount of fine particles generated at inhalation. Turbuhaler is more than twice as effective as Diskus at generating fine particles, and the higher lung deposition with Turbuhaler is accompanied by a lower variability in lung deposition. Compared with Diskus, the lung deposition with Turbuhaler is affected less by factors such as humidity.
治疗哮喘和慢性阻塞性肺疾病的药物应通过吸入方式局部给药。然而，并不存在一种理想的吸入器，即没有任何缺点且具备所有理想特性的“理想吸入器”。在这篇简短的综述中，我们比较了两种最常用的干粉吸入器——都保（Turbuhaler）和准纳器（Diskus）的相对优点。临床疗效与到达肺部的吸入药物量有关，而这又取决于吸入时产生的细颗粒量。都保产生细颗粒的效果比准纳器高出两倍多，都保较高的肺部沉积率伴随着较低的肺部沉积变异性。与准纳器相比，都保的肺部沉积受湿度等因素的影响较小。
